» Articles » PMID: 28027027

Estimating State Transitions for Opioid Use Disorders

Overview
Publisher Sage Publications
Date 2016 Dec 28
PMID 28027027
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: The aim was to estimate transitions between periods in and out of treatment, incarceration, and legal supervision, for prescription opioid (PO) and heroin users.

Methods: We captured all individuals admitted for the first time for publicly funded treatment for opioid use disorder (OUD) in California (2006 to 2010) with linked mortality and criminal justice data. We used Cox proportional hazards and competing risks models to assess the effect of primary PO use (v. heroin) on the hazard of transitioning among 5 states: (1) opioid detoxification treatment; (2) opioid agonist treatment (OAT); (3) legal supervision (probation or parole); (4) incarceration (jail or prison); and (5) out-of-treatment. Transitions were conditional on survival, and death was modeled as an absorbing state.

Results: Both primary PO (n = 11,733) and heroin (n = 19,926) users spent most of their median 2.3 y of observation out of treatment. Primary PO users were significantly younger (median age 30 v. 34 y), and a higher percentage were female (43.1% v. 31.5%; P < 0.001), white (74.6% v. 63.1%; P < 0.001), and had completed high school (31.8% v. 18.9%; P < 0.001). When compared to primary heroin users, PO users had a higher hazard of transitioning from detoxification to OAT (Hazard Ratio (HR), 1.65; 95% CI, 1.54 to 1.77), and had a lower hazard of transitioning from out-of-treatment to either detoxification (0.75 [0.70, 0.81]) or OAT (0.90 [0.85, 0.96]).

Conclusion: Our findings can be applied directly in state transition modeling to improve the validity of health economic evaluations. Although PO users tended to remain in treatment for longer durations than heroin users, they also tended to remain out of treatment for longer after transitioning to an out-of-treatment state. Despite the proven effectiveness of time-unlimited treatment, individuals with OUD spend most of their time out of treatment.

Citing Articles

Economic Evaluation in Opioid Modeling: Systematic Review.

Beaulieu E, DiGennaro C, Stringfellow E, Connolly A, Hamilton A, Hyder A Value Health. 2021; 24(2):158-173.

PMID: 33518022 PMC: 7864393. DOI: 10.1016/j.jval.2020.07.013.


Longitudinal trends in nonmedical prescription opioid use in a cohort of rural Appalachian people who use drugs.

Havens J, Knudsen H, Young A, Lofwall M, Walsh S Prev Med. 2020; 140:106194.

PMID: 32652132 PMC: 7680378. DOI: 10.1016/j.ypmed.2020.106194.


Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.

Krawczyk N, Mojtabai R, Stuart E, Fingerhood M, Agus D, Lyons B Addiction. 2020; 115(9):1683-1694.

PMID: 32096302 PMC: 7426244. DOI: 10.1111/add.14991.


Short-Term Effects and Long-Term Cost-Effectiveness of Universal Hepatitis C Testing in Prenatal Care.

Tasillo A, Yazdi G, Nolen S, Schillie S, Vellozzi C, Epstein R Obstet Gynecol. 2019; 133(2):289-300.

PMID: 30633134 PMC: 6501827. DOI: 10.1097/AOG.0000000000003062.


The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California.

Krebs E, Urada D, Evans E, Huang D, Hser Y, Nosyk B Addiction. 2016; 112(5):838-851.

PMID: 27981691 PMC: 5382102. DOI: 10.1111/add.13729.

References
1.
Evans E, Li L, Min J, Huang D, Urada D, Liu L . Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10. Addiction. 2015; 110(6):996-1005. PMC: 4452110. DOI: 10.1111/add.12863. View

2.
Hser Y . Predicting long-term stable recovery from heroin addiction: findings from a 33-year follow-up study. J Addict Dis. 2007; 26(1):51-60. DOI: 10.1300/J069v26n01_07. View

3.
Nielsen S, Hillhouse M, Mooney L, Ang A, Ling W . Buprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination users. J Subst Abuse Treat. 2014; 48(1):70-6. PMC: 4250309. DOI: 10.1016/j.jsat.2014.06.006. View

4.
Hser Y, Evans E, Grella C, Ling W, Anglin D . Long-term course of opioid addiction. Harv Rev Psychiatry. 2015; 23(2):76-89. DOI: 10.1097/HRP.0000000000000052. View

5.
Buck J . The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act. Health Aff (Millwood). 2011; 30(8):1402-10. DOI: 10.1377/hlthaff.2011.0480. View